Exploring the feasibility of monitoring access to novel medicines: A pilot study in EU Member States
Ensuring affordable access to novel medicines has been identified as a policy priority among OECD and EU countries, yet systematic monitoring of the various dimensions of access is lacking. Previous efforts to measure access have focused primarily on one or at most two of these dimensions, such as a...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | , |
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Paris
OECD Publishing
2023
|
| Schriftenreihe: | OECD Health Working Papers
no.151 |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Ensuring affordable access to novel medicines has been identified as a policy priority among OECD and EU countries, yet systematic monitoring of the various dimensions of access is lacking. Previous efforts to measure access have focused primarily on one or at most two of these dimensions, such as availability and affordability, but a more holistic picture is needed. The OECD undertook a pilot study in EU Member States that aimed to determine the utility and feasibility of routine, cross-national monitoring of access to medicines across multiple dimensions. The work included a desk review to define the dimensions of access and associated indicators, followed by an OECD survey to explore the feasibility of collecting and analysing the relevant data for a convenience sample of 15 recently authorised product/indication pairs. This working paper presents key learnings from the desk review and country survey to which 21 EU Member States responded, with a focus on exploring the utility and feasibility of the processes of monitoring and measurement. |
| Beschreibung: | 1 Online-Ressource (79 p.) 21 x 28cm. |
| DOI: | 10.1787/8c1d16c4-en |
Internformat
MARC
| LEADER | 00000cam a22000002 4500 | ||
|---|---|---|---|
| 001 | ZDB-13-SOC-092691293 | ||
| 003 | DE-627-1 | ||
| 005 | 20231204121453.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230515s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1787/8c1d16c4-en |2 doi | |
| 035 | |a (DE-627-1)092691293 | ||
| 035 | |a (DE-599)KEP092691293 | ||
| 035 | |a (FR-PaOEC)8c1d16c4-en | ||
| 035 | |a (EBP)092691293 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a I11 |2 jelc | ||
| 084 | |a I10 |2 jelc | ||
| 084 | |a I18 |2 jelc | ||
| 100 | 1 | |a Chapman, Suzannah |e VerfasserIn |4 aut | |
| 245 | 1 | 0 | |a Exploring the feasibility of monitoring access to novel medicines |b A pilot study in EU Member States |c Suzannah, Chapman, Anna, Szklanowska and Ruth, Lopert |
| 264 | 1 | |a Paris |b OECD Publishing |c 2023 | |
| 300 | |a 1 Online-Ressource (79 p.) |c 21 x 28cm. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a OECD Health Working Papers |v no.151 | |
| 520 | |a Ensuring affordable access to novel medicines has been identified as a policy priority among OECD and EU countries, yet systematic monitoring of the various dimensions of access is lacking. Previous efforts to measure access have focused primarily on one or at most two of these dimensions, such as availability and affordability, but a more holistic picture is needed. The OECD undertook a pilot study in EU Member States that aimed to determine the utility and feasibility of routine, cross-national monitoring of access to medicines across multiple dimensions. The work included a desk review to define the dimensions of access and associated indicators, followed by an OECD survey to explore the feasibility of collecting and analysing the relevant data for a convenience sample of 15 recently authorised product/indication pairs. This working paper presents key learnings from the desk review and country survey to which 21 EU Member States responded, with a focus on exploring the utility and feasibility of the processes of monitoring and measurement. | ||
| 650 | 4 | |a Social Issues/Migration/Health | |
| 700 | 1 | |a Szklanowska, Anna |e MitwirkendeR |4 ctb | |
| 700 | 1 | |a Lopert, Ruth |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-13-SOC |q FWS_PDA_SOC |u https://doi.org/10.1787/8c1d16c4-en |3 Volltext |
| 912 | |a ZDB-13-SOC | ||
| 951 | |a BO | ||
| 912 | |a ZDB-13-SOC | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-13-SOC-092691293 |
|---|---|
| _version_ | 1804748626234179584 |
| adam_text | |
| any_adam_object | |
| author | Chapman, Suzannah |
| author2 | Szklanowska, Anna Lopert, Ruth |
| author2_role | ctb ctb |
| author2_variant | a s as r l rl |
| author_facet | Chapman, Suzannah Szklanowska, Anna Lopert, Ruth |
| author_role | aut |
| author_sort | Chapman, Suzannah |
| author_variant | s c sc |
| building | Verbundindex |
| bvnumber | localFWS |
| collection | ZDB-13-SOC |
| ctrlnum | (DE-627-1)092691293 (DE-599)KEP092691293 (FR-PaOEC)8c1d16c4-en (EBP)092691293 |
| discipline | Wirtschaftswissenschaften |
| doi_str_mv | 10.1787/8c1d16c4-en |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02327cam a22003852 4500</leader><controlfield tag="001">ZDB-13-SOC-092691293</controlfield><controlfield tag="003">DE-627-1</controlfield><controlfield tag="005">20231204121453.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230515s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1787/8c1d16c4-en</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627-1)092691293</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)KEP092691293</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(FR-PaOEC)8c1d16c4-en</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EBP)092691293</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I11</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I10</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">I18</subfield><subfield code="2">jelc</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Chapman, Suzannah</subfield><subfield code="e">VerfasserIn</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Exploring the feasibility of monitoring access to novel medicines</subfield><subfield code="b">A pilot study in EU Member States</subfield><subfield code="c">Suzannah, Chapman, Anna, Szklanowska and Ruth, Lopert</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Paris</subfield><subfield code="b">OECD Publishing</subfield><subfield code="c">2023</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (79 p.)</subfield><subfield code="c">21 x 28cm.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">OECD Health Working Papers</subfield><subfield code="v">no.151</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Ensuring affordable access to novel medicines has been identified as a policy priority among OECD and EU countries, yet systematic monitoring of the various dimensions of access is lacking. Previous efforts to measure access have focused primarily on one or at most two of these dimensions, such as availability and affordability, but a more holistic picture is needed. The OECD undertook a pilot study in EU Member States that aimed to determine the utility and feasibility of routine, cross-national monitoring of access to medicines across multiple dimensions. The work included a desk review to define the dimensions of access and associated indicators, followed by an OECD survey to explore the feasibility of collecting and analysing the relevant data for a convenience sample of 15 recently authorised product/indication pairs. This working paper presents key learnings from the desk review and country survey to which 21 EU Member States responded, with a focus on exploring the utility and feasibility of the processes of monitoring and measurement.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Social Issues/Migration/Health</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Szklanowska, Anna</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lopert, Ruth</subfield><subfield code="e">MitwirkendeR</subfield><subfield code="4">ctb</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-13-SOC</subfield><subfield code="q">FWS_PDA_SOC</subfield><subfield code="u">https://doi.org/10.1787/8c1d16c4-en</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">BO</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-13-SOC</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-13-SOC-092691293 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-16T15:06:52Z |
| institution | BVB |
| language | English |
| open_access_boolean | |
| owner | DE-863 DE-BY-FWS |
| owner_facet | DE-863 DE-BY-FWS |
| physical | 1 Online-Ressource (79 p.) 21 x 28cm. |
| psigel | ZDB-13-SOC |
| publishDate | 2023 |
| publishDateSearch | 2023 |
| publishDateSort | 2023 |
| publisher | OECD Publishing |
| record_format | marc |
| series2 | OECD Health Working Papers |
| spelling | Chapman, Suzannah VerfasserIn aut Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States Suzannah, Chapman, Anna, Szklanowska and Ruth, Lopert Paris OECD Publishing 2023 1 Online-Ressource (79 p.) 21 x 28cm. Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier OECD Health Working Papers no.151 Ensuring affordable access to novel medicines has been identified as a policy priority among OECD and EU countries, yet systematic monitoring of the various dimensions of access is lacking. Previous efforts to measure access have focused primarily on one or at most two of these dimensions, such as availability and affordability, but a more holistic picture is needed. The OECD undertook a pilot study in EU Member States that aimed to determine the utility and feasibility of routine, cross-national monitoring of access to medicines across multiple dimensions. The work included a desk review to define the dimensions of access and associated indicators, followed by an OECD survey to explore the feasibility of collecting and analysing the relevant data for a convenience sample of 15 recently authorised product/indication pairs. This working paper presents key learnings from the desk review and country survey to which 21 EU Member States responded, with a focus on exploring the utility and feasibility of the processes of monitoring and measurement. Social Issues/Migration/Health Szklanowska, Anna MitwirkendeR ctb Lopert, Ruth MitwirkendeR ctb FWS01 ZDB-13-SOC FWS_PDA_SOC https://doi.org/10.1787/8c1d16c4-en Volltext |
| spellingShingle | Chapman, Suzannah Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States Social Issues/Migration/Health |
| title | Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States |
| title_auth | Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States |
| title_exact_search | Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States |
| title_full | Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States Suzannah, Chapman, Anna, Szklanowska and Ruth, Lopert |
| title_fullStr | Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States Suzannah, Chapman, Anna, Szklanowska and Ruth, Lopert |
| title_full_unstemmed | Exploring the feasibility of monitoring access to novel medicines A pilot study in EU Member States Suzannah, Chapman, Anna, Szklanowska and Ruth, Lopert |
| title_short | Exploring the feasibility of monitoring access to novel medicines |
| title_sort | exploring the feasibility of monitoring access to novel medicines a pilot study in eu member states |
| title_sub | A pilot study in EU Member States |
| topic | Social Issues/Migration/Health |
| topic_facet | Social Issues/Migration/Health |
| url | https://doi.org/10.1787/8c1d16c4-en |
| work_keys_str_mv | AT chapmansuzannah exploringthefeasibilityofmonitoringaccesstonovelmedicinesapilotstudyineumemberstates AT szklanowskaanna exploringthefeasibilityofmonitoringaccesstonovelmedicinesapilotstudyineumemberstates AT lopertruth exploringthefeasibilityofmonitoringaccesstonovelmedicinesapilotstudyineumemberstates |